Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Neuropathic Pain in 15 Major Markets
Neuropathic pain is generally defined as chronic pain resulting from injury to the nervous system. Neuropathic pain is caused by other conditions or diseases such as diabetes or herpes zoster infection, and is often accompanied by depression, sleep disturbances and fear/anxiety. Nerve fibres may be damaged or dysfunctional, causing incorrect signals to other pain centres.
This report provides the current prevalent population for Neuropathic Pain across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Netherlands, Australia, Canada and Poland) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Neuropathic Pain have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Neuropathic Pain include:
Abnormal sensations – e.g. paresthesia, allodynia, algesia
Myelomas and some forms of Non-Hodgkin Lymphoma
Type 2 Diabetes Mellitus
Herpes zoster (shingles)
Chronic lower back pain
Multiple sclerosis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Able to quantify patient populations in global Neuropathic Pains market to target the development of future products, pricing strategies and launch plans.
Gain further insight into the prevalence of the subdivided types of Neuropathic Pain and identify patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Provide a level of understanding on the impact from specific co-morbid conditions on Neuropathic Pains prevalent population.
Identify sub-populations within Neuropathic Pain which require treatment.
Gain an understanding of the specific markets that have the largest number of Neuropathic Pain patients.
Table of Contents
List of Tables and Figures
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions /Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Additional data available on request
Top-Line Prevalence for Neuropathic Pain
Features of Neuropathic Pain Patients
Severity of Neuropathic Pain
Aetiology of Neuropathic Pain
Symptoms of Neuropathic Pain
Location and Duration of Neuropathic Pain
Physical Sensations of Neuropathic Pain
Abbreviations and Acronyms used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix
List of Tables
1. Prevalence of Neuropathic Pain, total (000s)
2. Prevalence of Neuropathic Pain, males (000s)
3. Prevalence of Neuropathic Pain, females (000s)
4. Severity of Neuropathic Pain in patients, total (000s)
5. Aetiology of Neuropathic Pain, total (000s)
6. Months (M) of Pain duration in Neuropathic Pain patients, total (000s)
7. Prevalence of upper limb pain in Neuropathic Pain patients, total (000s)
8. Prevalence of lower limb pain in Neuropathic Pain patients, total (000s)
9. Prevalence of neck/shoulder pain in Neuropathic Pain patients, total (000s)
10. Prevalence of numbness feeling in Neuropathic Pain patients, total (000s)
11. Prevalence of squeezing feeling in Neuropathic Pain patients, total (000s)
12. Prevalence of lancinating feeling in Neuropathic Pain patients, total (000s)
13. Abbreviations and acronyms used in the report
14. USA Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
15. USA Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
16. France Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
17. France Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
18. Germany Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
19. Germany Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
20. Italy Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
21. Italy Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
22. Spain Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
23. Spain Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
24. United Kingdom Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
25. United Kingdom Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
26. Brazil Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
27. Brazil Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
28. Japan Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
29. Japan Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
30. India Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
31. India Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
32. MexicPrevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
33. MexicPrevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
34. Turkey Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
35. Turkey Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
36. Netherlands Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
37. Netherlands Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
38. Australia Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
39. Australia Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
40. Canada Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
41. Canada Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
42. Poland Prevalence of Neuropathic Pain by 5-yr age cohort, males (000s)
43. Poland Prevalence of Neuropathic Pain by 5-yr age cohort, females (000s)
